🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Huseyin Naci

Norwich University

ORCID: 0000-0002-7192-5751

Also affiliated with Office Of Health Economics, Harvard Pilgrim Health Care, London School of Economics and Political Science

Economics, Econometrics and FinanceDecision SciencesPharmacology, Toxicology and Pharmaceutics

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile
13.9Author DataRank

Indexed papers

2in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Top data-sharing exemplar

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study

BMJ(2013)10.1136/bmj.f5577
Top 2%
8.0DataRank
Top 2%639 citations

Huseyin Naci, John P. A. Ioannidis

Papers

Driven by 8 papers — median percentile 97. Top paper: “Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study”.

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study

BMJ(2013)10.1136/bmj.f5577
Top 2%
8.0DataRank
Top 2%639 citations

Huseyin Naci, John P. A. Ioannidis

Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study

British Journal of Sports Medicine(2015)10.1136/bjsports-2015-f5577rep
Top 3%
5.9DataRank
Top 3%205 citations

John P. A. Ioannidis, Huseyin Naci

Evaluation of Wellness Determinants and Interventions by Citizen Scientists

JAMA(2015)10.1001/jama.2015.6160
N/A
5.5DataRank · unranked
105 citations

John P. A. Ioannidis, Huseyin Naci

How Good Is “Evidence” from Clinical Studies of Drug Effects and Why Might Such Evidence Fail in the Prediction of the Clinical Utility of Drugs?

Annual Review of Pharmacology and Toxicology(2015)10.1146/annurev-pharmtox-010814-124614
N/A
3.8DataRank · unranked
70 citations

John P. A. Ioannidis, Huseyin Naci

Generating comparative evidence on new drugs and devices after approval

The Lancet(2020)10.1016/s0140-6736(19)33177-0
N/A
3.6DataRank · unranked
89 citations

John P. A. Ioannidis, Peter M. Rothwell, Paul Glasziou, Tianjing Li, Adrian F. Hernandez +4 more

Timing and Characteristics of Cumulative Evidence Available on Novel Therapeutic Agents Receiving Food and Drug Administration Accelerated Approval

The Milbank Quarterly(2017)10.1111/1468-0009.12261
N/A
3.2DataRank · unranked
59 citations

OLIVIER J. WOUTERS, RADHIKA GUPTA, John P. A. Ioannidis, Huseyin Naci

Infographic. How does exercise treatment compare with antihypertensive medications?

British Journal of Sports Medicine(2019)10.1136/bjsports-2019-101522
N/A
0.104DataRank · unranked
1 citations

Huseyin Naci, Pedro L. Valenzuela, Maximilian Salcher-Konrad, Sofia Dias, Manuel R. Blum +9 more

Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis

The Lancet Oncology(2025)10.1016/s1470-2045(25)00329-8
N/A
0DataRank · unranked
9 citations

Dingyi Chen, Mengyuan Fu, Luwen Shi, Huseyin Naci, Anita K. Wagner +3 more